CD38 expression does not change in B-cell chronic lymphocytic leukemia

D’Arena, Giovanni; Nunziata, Giuseppe; Coppola, Giuseppe; Vigliotti, Maria Luigia; Tartarone, Alfredo; Carpinelli, Nicola; Matera, Rosella; Bisogno, Rosario Colella; Gr, Pistolese; Renzo, Nicola Di

doi:10.1182/blood-2002-07-2249

Cited by 17 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this group of patients with stable CD38 expression, disease progression and relapse after a firstline chemotherapy did not modify this parameter. These results are in line with others (Damle et al, 1999;D'Arena et al, 2002;Ghia et al, 2003;Thornton et al, 2004), who reported the stability of CD38 expression during the course of the disease in 94-100% of CLL patients. Taken together, the results of this study, carried out on a large series of accurately defined CLL cases, studied on fresh material at presentation, indicate that CD38 is expressed in a relatively small proportion of patients, that the presence of ‡7% CD38 + CLL lymphocytes is already associated with bad prognostic parameters, as male sex, advanced Rai stage, lower Hb concentration, platelet count and higher lymphocyte count.…”

Section: Discussionsupporting

confidence: 92%

The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience

et al. 2005

View full text Add to dashboard Cite

SummaryThe purpose of this study was to assess in chronic lymphocytic leukaemia (CLL) patients the prevalence and clinical impact of CD38 expression, evaluated prospectively at disease presentation, and to verify whether this parameter changes over time. In 242 consecutive and untreated CLL patients, the percentage of CD38 + cases, according to the 7%, 20% and 30% cut-off points, was 21%, 17% and 14%, respectively. Using the 7% threshold, CD38 positivity correlated with male sex, intermediate and high-risk (Rai I-IV) disease, lower Hb and platelet levels, and higher lymphocyte count. Furthermore, patients with a CD38 expression ‡7% showed a significantly lower 3-year probability of treatment-free survival (TFS) than CD38) patients (P < 0AE0001). At multivariate analysis, CD38 expression remained significantly associated to TFS, together with stage, lymphocyte count and morphology. Also, in the 146 patients with stage 0 CLL a CD38 expression ‡7% identified a subgroup of patients with a significantly lower 3-year probability of TFS (P ¼ 0AE0005). Furthermore, this parameter did not change in 30 of 31 (97%) re-evaluated patients. In conclusion, this study indicates that, when tested at diagnosis and on fresh material, a CD38 expression ‡7% is an important parameter for the identification of early CLL patients with more aggressive disease and that its expression remains stable over time.

show abstract

Section: Discussionsupporting

confidence: 92%

The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In our laboratory (Kipps) we have found that the expression of CD38 is stable (36). Our investigation of 10 patient samples over a period of 4 years confirms previous analyses that CD38 expression is stable over time (8,10,(13)(14)(15)31,35,37 Appendix B).…”

Section: Considerations For the Measurement Of Cd38supporting

confidence: 86%

“…The expression of CD38 expression has been shown to be unstable over time in some patients and not in others (8)(9)(10)12,14,(29)(30)(31)(32)(33)(34) and there has been disagreement about which cutoff value to use for CD38 positivity for defining prognosis. Some investigators have used 7% (14,15,18,28), others 20% (10,13), and still others 30% (8,9,11,12,31). Thornton et al and Ghia et al reported that CD38 expression did not change over an interval of greater than 8 years (15,32,35).…”

Section: Considerations For the Measurement Of Cd38mentioning

confidence: 99%

Clinical utility of assessing ZAP‐70 and CD38 in chronic lymphocytic leukemia

Rassenti

Kipps

2006

Cytometry Part B Clinical

View full text Add to dashboard Cite

“…9,13,32,34 Since our proposal is to use CD69 for prognostic purposes, we confirmed its inter-laboratory reproducibility and the stability over time of its expression. 21,35 We demonstrated that CD69 expression was significantly correlated with CD38, CD49d and ZAP-70 and IGHV mutational status. CD69 that is up-regulated rapidly with cellular activation resembling B cells at an earlier state of activation, might be able to transduce BCR-mediated signals better with the help of simultaneous ZAP-70 expres-CD69 expression in CLL haematologica | 2012; 97 (2) 283 …”

Section: Discussionmentioning

confidence: 83%

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study

Poeta

Principe²,

Zucchetto³

et al. 2011

Haematologica

View full text Add to dashboard Cite

BackgroundCD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. Design and MethodsWe investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. ResultsCD69 was associated with Rai stages (P=0.00002), b2-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69 + plus ZAP-70 + or CD38 + or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of b2-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039). ConclusionsOur data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process.

show abstract

CD38 expression does not change in B-cell chronic lymphocytic leukemia

Cited by 17 publications

References 11 publications

The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience

The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience

Clinical utility of assessing ZAP‐70 and CD38 in chronic lymphocytic leukemia

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study

Contact Info

Product

Resources

About